Supplemental Figure S7 and Figure S8 from Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia <i>In Vitro</i> and <i>In Vivo</i>

Abstract

&lt;p&gt;Supplemental Figure S7 and Figure S8. Characterization of sublines established from in vivo treatment of the MV4;11 xenograft tumors in mice with SAR or ABT-263 for their response to SAR (Figure S7) or to ABT-263 (Figure S8).&lt;/p&gt;